Promising results of umbilical cord blood transplantation (UCBT) from unrelated donors have been reported in patients with hematologic disorders. These transplants, having potential to trigger beneficial donor-versus-recipient natural killer (NK) cell-mediated alloreaction, we have conducted the first extensive analysis of the phenotypic and functional properties of NK cells after UCBT. NK cells from 25 patients with high-risk hematologic malignancies were compared with cells derived from both healthy adult and CB cells. We found that following UCBT, NK cells display not only some phenotypic features associated with maturity but also unique characteristics that make them fully functional against leukemic blasts. We propose that this full functionality of alloreactive donor-derived NK may drive graft-versus-leukemia reactions after UCBT.
Introduction
Human natural killer (NK) cells are innate immune lymphocytes that held early clinical promise because of their ability to lyse leukemic cells without specific antigen recognition. Progress in the field of NK-cell receptor has revolutionized our concept of how NK cells recognize and lyse leukemic cells while sparing normal cells. NK cells accomplish this task by balancing or integrating the signals that are transmitted through stimulatory and inhibitory receptors and that regulate their functional capacities to engage the target cells directly. 1 NK cells are equipped with a large number of cell-surface markers, including killer cell immunoglobulin-like receptors (KIRs), C-type lectin (NKG2A, NKG2C and NKG2D) and natural cytotoxicity receptors (NKp30, NKp44 and NKp46). Functionally, NK cells are characterized by several important functions, including their capacity to spontaneously lyse susceptible targets. Natural killing involves exocytosis of perforin-and granzyme-containing cytoplasmic granules through a metabolically active process. An equally important function of NK cells involves their capacities to promptly produce cytokines, notably interferon (IFN)-g, and in some cases, granulocyte macrophage colony-stimulating factor or interleukin (IL)-10. Together, these functional activities place NK cells in a crossroad position to actively eliminate susceptible targets through multiple and non-redundant mechanisms. 2 After transplantation, the distinct cell lineages of the developing immune system reconstitute at highly different rates; T-cell recovery is very low, but new NK cells are prevalent and integrate this system within 2-3 weeks, suggesting that NK cells could play a remarkable role following hematopoietic transplantation. 3, 4 Treatment of leukemia with transplantation of allogenic bone marrow or stem cells from peripheral blood stem cells is limited by the scarcity of human leukocyte antigen (HLA)-matched related or unrelated donor; only 50-60% of patients are eligible. Pioneering results of Ruggeri et al. 5 have reported that allogeneic NK cells can mediate antileukemic effects against acute myeloid leukemia (AML) after haploidentical hematopoietic stem-cell transplantation (HSCT), with KIR ligand/KIR ligand incompatibility in the graft-versus-host (GvH) direction. 6 However, beneficial effect of KIR ligand incompatibility is controversial, especially in advanced hematologic diseases. 7, 8 We have revealed earlier that NK cells generated after haploidentical HSCT are blocked at an immature state characterized by specific phenotypic features and impaired functioning that may negatively affect transplantation outcome. 9, 10 There is considerable evidence that placental blood, obtained from umbilical cord at delivery, is a promising source of hematopoietic stem cells. The establishment of international cord blood (CB) banks, advances in supportive care and donor graft selection, and novel clinical approaches aimed at improving engraftment have better outcomes and have led to a dramatic increase in the number of umbilical CB transplantation (UCBT) performed worldwide. 11 This emerging therapy for adult patients without matched donors offer advantages over bone marrow or peripheral blood stem cells transplantations, such as non-invasive procurement, more rapid availability without the lengthy process of screening and obtaining stem cells from a matched unrelated donor. [12] [13] [14] [15] Moreover, large international studies strongly suggested that UCBT has the advantages of greater tolerance of HLA disparity, lower incidence of GvH disease and possible identical graft-versusleukemia (GvL) effect, compared with unrelated bone marrow transplantation. [16] [17] [18] To our knowledge, this study represents the first extensive study of NK cells in adult patients after UCBT. We have longitudinally monitored the post-graft phenotypic expression of a large panel of NK receptors, as well as their cytolytic function against primary leukemic blasts. Our data revealed that NK cells following UCBT display not only some phenotypic features associated with maturity in current models, but also unique characteristics, sufficient to acquire efficient cytolytic activities against leukemic blasts. Importantly, our data suggested that fully functional alloreactive NK cells might play a crucial role to mediate GvL effect and improve clinical outcome.
Materials and methods

Patients and clinical outcome
Patient characteristics are summarized in Table 1 . These 25 patients (median age, 43.5 years) underwent UCBT between 2005 and 2008 at either Pitié-Salpêtrière or Hô tel Dieu hospital for high-risk hematopoietic malignancies. AML was the most common diagnosis (14/26) . All patients received a reducedintensity conditioning regimen; 20 patients received the Minneapolis protocol containing cyclophosphamide 50 mg/kg at day 6, fludarabine 200 mg/m 2 for 5 days and total body irradiation 2 Gy. For the last five patients, total body irradiation was replaced by 140 mg/m 2 of melphalan. Cyclosporine and mycophenolate mofetyl were given 3 days before transplantation to intensify the immunosuppressive conditioning and prevent GvH disease. Generic HLA-A, HLA-B and allelic HLA-DR typing was used in the matching strategy; most of the CB pairs were 4/6 matches. Patients and donors provided informed consent in compliance with the Ethics Committee guidelines before peripheral blood samples were collected for the study.
HLA typing
HLA-A, -B and -DR were serologically determined. The INNOLipa kit (Abbott Laboratories, Abbott park, IL, USA) was used to type HLA-C with PCR sequence-specific oligonucleotides. . Fluorescence-activated cell sorting lysing solution (Becton Dickinson) was used to lyse erythrocytes. At least 20 000 leukocytes were analyzed on an FC500 (Beckman Coulter). For intracellular staining, peripheral blood mononuclear cells were incubated overnight in the presence of IL-12 (10 ng/ml) and IL-18 (100 ng/ml) (R&D Systems). Cells were fixed and permeabilized with cytofix/cytoperm kit (Becton Dickinson), and then stained with anti-IFN-g (B27; Becton Dickinson), anti-perforin (dG9; AbCam) or anti-granzyme B (Gb11; AbCam, Paris, France) monoclonal antibodies, as described. 10 
Flow cytometry
NK degranulation, ADCC and cytolytic assays
Direct cytolytic activity of NK cells was assessed in a standard 4-h 51 Cr-release assay on peripheral blood mononuclear cell, cultured in the presence of 100 IU/ml of IL-2 for 48 h, against either K562 cells or primary leukemic blasts from AML patients, as described. 9 Antibody dependent cellular cytotoxicity (ADCC) experiments were performed on non-activated peripheral blood mononuclear cell against Raji cells, in the presence of 1 mg/ml of anti-CD20 RituxiMab. The degranulation assay was tested by CD107a (H4A3; Becton Dickinson) detection, as described. 10 
Statistics
All statistical analyses were performed using the Prism 4 software (GraphPad Software, San Diego, CA, USA). Intergroup comparisons were assessed using the Mann-Whitney U test, with significance defined by Po0.05 using a two-tailed test. 1*:Po0.05; 2*:Po0.01; 3*:Po0.001.
Results
Clinical outcomes
Twenty-five CB transplant recipients who underwent transplantation during the study period were assessed, with a median follow-up of 225 days (Table 1) . Fourteen patients have received one or two previous stem cell transplantations including autologous transplant before UCBT. Neutrophil engraftment 
Median before neutrophils 4500 Abbreviations: CMV, cytomegalo virus; GvHD, graft-versus-host disease.
Functional NK cells after UCBT V Beziat et al occurred at a median of 20 days. The incidence of the relapse was 28% (7/25) and was the major cause of death in six patients. The cumulative incidence of grade II and III acute graft-versus-host disease was 32%. No acute grade IV graft-versus-host disease occurred. Infection occurred only in two patients (8%). The free relapse survival rate was 68% at 6 months, as described earlier. 16, 17 Importantly, only 4/25 of donor-patient pairs presented a KIR-ligand mismatch in the GvH direction: one patient died of relapse, one patient of infection, whereas the two other patients are still alive (Table 1 and data not shown). It is worth noting that analysis of DNA polymorphisms in the peripheral blood showed a donor-type chimerism of around 99.3% (Q1 ¼ 70.5%; Q3 ¼ 99.9%), at 1 month after UCBT (Table 1) .
NK-cell reconstitution after UCBT
Flow cytometry was used to measure CD3 þ T, CD19 þ B and CD3 À CD56 þ NK subsets in recipients throughout the follow-up and compared them with healthy donors. The distribution of lymphocyte subsets after UCBT showed that B and T lymphocytes were barely detectable after transplantation and remained significantly lower than in adult controls during the first 2 months for B cells and during 6 months for T cells (Figure 1 ). In contrast, CD3
À CD56 þ NK cells were detectable in all recipients soon after transplantation at similar or slightly higher level than in the control group, in percentage and absolute value ( Figure 1 ). Human NK cells can be divided into CD56 bright and CD56 dim populations, based on their cell-surface density of CD56 molecules, which present distinct phenotypic and functional properties; 19 the CD56 bright subset was significantly higher, than in NK cells from adult and CB samples, during the first 12 months post-UCBT (Figure 1 ).
Phenotypic analysis of NK-receptor repertoire after UCBT
We further compared the phenotypic properties of a more restricted NK-cell subset by gating out CD56 bright NK cells from our analysis to focus our study on CD56 dim cytotoxic NK cells. The expression of CD94/NKG2A was sharply higher after UCBT (median 85.4±9.7%) and in CB (median 83.2±8.7%) than in adult control samples (median 49.6 ± 11.9%) (Figure 2a) . A similar pattern was observed for CD94, which is strictly associated with NKG2A (data not shown). By contrast, the level of NKG2C was similar in all samples, and the level of NKG2D slightly decreased after UCBT (Figure 2a ). More interestingly, the expression of KIR2DL2-L3/DS2, which binds group-1 HLACw ligands, and of KIR3DL1/DS1, which recognizes HLA-Bw4, was similar to that in healthy adult controls, but significantly higher than in CB NK samples (Figure 2b ). In contrast, the expression of KIR2DL1/DS1, which recognizes group-2 HLA-C alleles, was significantly lower than that in adult controls during the first 6 months post-UCBT (Figure 2b) .
Furthermore, the expression of two major specific activating NK receptors increased after engraftment: at 1 month post-UCBT, levels of both NKp30 and NKp46 were significantly higher than in either control group (P ¼ 0.0089 and P ¼ 0.0002, respectively). This effect persisted for at least the first 2 months (Figure 2c) . Finally, these post-UCBT CD56 dim NK cells were indistinguishable from adult and CB control samples for cell-surface expression of the other receptors tested, including natural cytotoxicity receptors (NKp44 and NKp80), 2B4 and LAIR1 (data not shown). Notably, early during recovery from UCBT, there was a substantially higher frequency of CD56 dim NK cells, which express CD69, an early cell-activation marker, than in either set of control samples. This expression was transient and returned to normal values by 3 months after UCBT (Figure 2d) .
Interestingly, early after recovery, patients' NK cells showed specific phenotypic characteristics never observed in the donor CB NK cells. Specifically, these CB NK cells expressed very low levels of both ILT2 and DNAM-1, as reported earlier. 20 At 1 month after UCBT, however, the level of ILT2 in patients was close to that in control adult NK cells, and DNAM-1 expression was sharply higher than in the CB NK cells (Figure 2d ). This indicates that during the early stages of recovery after UCBT, mature NK cells Functional NK cells after UCBT V Beziat et al were rapidly generated, indicative of a high capacity for maturation, like that observed in adult peripheral blood.
Other specific markers were analyzed to determine the developmental potential of these NK cells using antibodies recognizing surface antigens present on mature NK cells. 21 Pen-5, which is presented exclusively on terminally differentiated CD56 dim cytotoxic NK cells, 22 was expressed during early recovery from UCBT in proportions similar to those in NK cells from healthy adults and CB (Figure 3) . Similarly, CD8a, an activating ligand for cytotoxicity on mature NK cells, 23 was also sharply expressed following transplantation, but remained around two times lower during the first 12 months post-transplantation, than in healthy individuals (data not shown). Interestingly, a similar pattern of expression was also observed for CD161, another maker differentially expressed during the NK-cell differentiation (Figure 3) . Together, these results demonstrate that a substantial proportion of NK cells rapidly acquire the phenotypic capacities of mature NK cells after UCBT.
Functional analysis of NK cells generated after UCBT
To determine the significance of these findings, we assessed the overall functional ability of NK cells following UCBT. As Figure 4a shows, the NK cells produced intracellular IFN-g after treatment with IL-12 and IL-18; at 1 month post-UCBT, the response was higher in the NK cells from CB and patients than in the healthy controls. At 3 months post-graft, however, the proportion of IFN-g þ cells in patients returned to values similar to those in healthy adult controls. Enzyme-linked immunosorbent assays confirmed these findings (Figure 4b) .
Direct cytotoxicity against HLA class I-negative K562 target cells was similar for healthy adults and patients at all times tested after transplantation. To confirm the cytolytic data, we tested their degranulation capacities. Consistent with the NK cytotoxicity data, the proportion of NK cells expressing CD107a remained similar in all sample groups (Figure 4c) . Furthermore, similar levels of perforin and granzyme-B were detected in controls and patients after UCBT (data not shown). More importantly, further studies used primary blasts from various HLA-mismatched AML patients, as target cells. These leukemic cells were first analyzed for susceptibility to killing by NK cells from either healthy adult or CB donors. As shown in Figure 4d , all AML blast cells were susceptible to killing by these NK cells. Interestingly, NK cells derived from UCBT recipients showed a similar distribution of cytolytic activity against primary blasts, than the control NK cells (Figure 4d ). The variability of the 
Functional NK cells after UCBT
V Beziat et al cytotoxic responses observed in all samples from healthy controls and patients following UCBT might be due to the extreme polymorphism of both the HLA class I and KIR loci in the human population, which directly influences the responsive capacity of NK cells bearing cognate and non-cognate NK-cell receptors. 24 It is worth noting that for the first 3 months after UCBT, NK cells responded poorly to antibody-dependent cellmediated cytotoxicity at the same time that they expressed relatively little CD16 (Figure 4e ). These findings are consistent with the high proportion of NK CD56 bright cells, which do not strongly exhibit the CD16 marker, generally observed after HSCT. 25 
Discussion
Hematopoietic transplantation offers a unique opportunity to assess the effect of NK-cell reconstitution on GvL effect. In this study, we showed an early recovery of mature NK cells following UCBT, compared with other lymphocytic cell subsets, revealing the putative key role of these cells. Following UCBT, the NK cells that represent the great majority of circulating lymphocytes, at 1 month post-transplantation, were usually accompanied by a disproportional increase in the ratio of CD56 bright to CD56 dim NK cells and a high expression of CD94/ NKG2A-inhibitory receptor. Consistent with these in vitro data, several studies have reported that NK cells following matched or mismatched HSCT are characterized by specific phenotypic features including a very low proportion of KIR-positive NK cells inversely correlated with their high expression of CD94/ NKG2A. 9, 26, 27 Indeed, in vitro analysis of NK-cell differentiation from CD34 þ stem cells revealed that most of the immature NK cells expressed a high level of CD56 bright surface antigen. 28 In addition, NK-receptor acquisition is an orderly process during NK development, where CD94/NKG2A is first expressed, and followed by acquisition of KIR. [28] [29] [30] [31] [32] Interestingly, in this study, we showed that following transplantation, NK cells also displayed major phenotypic features associated with maturity. Indeed, we observed that in spite of the persistent overexpression of CD94/NKG2A, the patterns of NK-cell receptor expression during the first year after SCT revealed great similarity with mature NK cells from healthy donors, including major KIRs, NKG2C NKG2D, NKp44, NKp80, ILT2, 2B4 and LAIR1. Furthermore, two major specific activating NK-cell receptors, NKp30 and NKp46, thought to be downmodulated after HSCT, 9, 33 are significantly overexpressed following UCBT. The high level of these NK-cell receptors might be consistent with a mature NK phenotype. In addition, the rapid and significant expression of Pen5, CD8a and CD161, three independent NK-cell markers of maturation, reinforced the concept that following UCBT, a large fraction of NK cells easily obtained a fully functional status.
In agreement with these phenotypic observations, NK cells are functionally competent after UCBT. They produced large amounts of IFN-g and have a degranulation propensity comparable with normal NK cells. We observed that a significant fraction of NK cells presents impressive functional capacities against K562 cells and primary AML blasts, closed to the level observed with mature NK cells from healthy adult donors, but highly enhanced as compared with cells generated following haploidentical HSCT. 9, 34 These important clues suggest that the rapid appearance of NK-cell functioning after UCBT is mainly Functional NK cells after UCBT V Beziat et al due to the rapid maturation of NK cells. This is revealed by the normal level of expression of the great majority of NK receptors and also by the strongly increased expression of the major specific activating NK-cell receptors, NKp30 and NKp46, which could indirectly override NKG2A-inhibitory signal to allow NK cells to eliminate leukemic cells. Thus, our results reveal major phenotypic and functional differences between NK cells generated after UCBT and after other SCT, differences being likely to affect immune response and transplantation outcome.
Several studies reported the impact of the quality of NK-cell reconstitution on clinical outcome after SCT. Shilling et al. 26 show that patients who have a delay on NK reconstitution after HLA-matched SCT presented more severe clinical complications than those who reconstituted more rapidly. In the same line, Savani et al. 35 suggested that early NK recovery was a main predictor of molecular remission in Chronic myelogenous leukemia patients undergoing HLA-matched T-cell-depleted transplants. More recently, we and other groups have also reported an altered NK reconstitution after haploidentical SCT, having potential impact on GvL effect. 9, 10, 36 Interestingly, recovering NK cells following UCBT presents specific phenotypic features as compared with NK cells from the CB graft, including the rate of cell-activation properties and the expression of specific markers. 20, 37 The maturation of NK cells occurs under the influence of the microenvironment and the host marrow stromal cells. 34 , 35 Lucas et al. 38 show that the intensity and quality of NK-cell cytotoxic response depend on the cytokine microenvironment as well as on immune system interactions. Several publications have focused on the newly described crosstalk between NK cells and dendritic cells or T lymphocytes, occurring in secondary compartments such as lymph nodes. [39] [40] [41] [42] This first encounter could promote NK cell maturation, cytotoxicity and IFN-g release. 43 , 44 Interestingly, we have shown that mature hematopoietic cells in graft of recipients who underwent haploidentical HSCT may play a key role in NK-cell differentiation, despite the GvH disease reaction. 10 Similarly, Bethge et al. 45 also suggested that depleting haploidentical graft in T and B mature cells, rather than performing an extensive CD34
þ -positive selection, may enhance immune reconstitution and clinical outcome by letting mature NK cells, monocytes and 'facilitating cells' in the infused graft. As compared with transplantations realized with highly purified CD34 þ stem cells, UCBTs are performed with in a particular hematopoietic environment, enriched on stem cells, and also including several other hematopoietic cell subsets at various differentiation stages. We can easily rule out the possibility that persistent immature T cells provided from the CB graft exert a significant effect on GvL reaction. [14] [15] [16] [17] This type of transplantation is characterized by a rapid recovery of NK cells and also a long and severe long-lasting T-cell immunoincompetence. The naive T cells within the CB graft are antigen inexperimented. As currently described, CB contains only little Functional NK cells after UCBT V Beziat et al or no cytotoxic T cells directed against viral and bacterial peptides, which may cross-react with HLA alloantigens, and thus may be responsible for the lower-than-expected frequency of severe GvH disease, even in the setting of one or two HLA mismatched. 46, 47 Similarly, in this study, less than 32% of patients presented an acute grade II or III GvH disease, and no patient presented an acute grade IV graft-versus-host disease, which could be due to the lack of post-thymic T cells and the naivety of the T-cell function after UCBT observed earlier after haploidentical HSCT. 48, 49 However, we have shown earlier that following haploidentical HSCT, relapse occurred in the early post-transplantation period in 7-10 patients (70%), despite the KIR-ligand incompatibility between donor and recipient. 9 By contrast, in this study, following UCBT, relapse has been observed in only 7-25 patients (28%), according to the results described earlier, although, we cannot formally conclude on the impact of KIR-ligand mismatch due to the weak number of patients in these studies. [13] [14] [15] [16] [17] [18] 50 Collectively, this study shows that following UCBT, NK cells appeared very rapidly and became fully functional against AML blasts. This strongly suggested that UCBT creates optimal conditions for sufficient NK-cell recovery required for disease control. These findings will shield a light in the key role of NK cells on the clinical paradox observed following UCBT consisting of a strong GvL effect associated with a low incidence of GvH disease, despite the persistent immaturity of T cells present in the unrelated CB graft.
